WO2003013538A1 - Oral dosage form comprising a therapeutic agent and an adverse-effect agent - Google Patents
Oral dosage form comprising a therapeutic agent and an adverse-effect agent Download PDFInfo
- Publication number
- WO2003013538A1 WO2003013538A1 PCT/US2002/024889 US0224889W WO03013538A1 WO 2003013538 A1 WO2003013538 A1 WO 2003013538A1 US 0224889 W US0224889 W US 0224889W WO 03013538 A1 WO03013538 A1 WO 03013538A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- oral dosage
- agents
- composition
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- This invention relates generally to an oral dosage form comprising a therapeutic agent and an adverse-effect agent.
- opioids are excellent analgesic agents that can control severe and/or chronic pain, such as cancer pain and post-operative pain, but are also subject to abuse by drug users.
- Opioids also known as opioid agonists, are a group of drugs that exhibit opium- or morphine-like properties. Opioids are employed primarily as moderate to strong analgesic agents, but provide other pharmacological effects as well.
- Prior art approaches to this problem have involved combining an opioid with an opioid antagonist. When administered orally, these combinations provide the pharmacologic action of the opioid with minimal action of the antagonist. When administered parenterally, however, the antagonist can be profoundly antagonistic to the opioid.
- Particular examples of such combinations include compositions comprising naloxone and morphine or oxymorphone (U.S. Patent No. 3,493,657 to Lewenstein et al.); methadone and naloxone (U.S. Patent No. 3,773,955 to Pachter et al.); methadol or acetyl methadol and naloxone (U.S. Patent No.
- U.S. Patent No. 6,228,863 to Palermo et al. discloses an oral dosage form of an opioid agonist and an opioid antagonist that reduces the abuse potential of the opioid by combining the agonist and antagonist such that at least two steps are required to separate them.
- U.S. Patent No. 5,935,975 to Rose et al. discloses a method for treating drug dependency by the combined administration of the drug or an agonist of the drug and an antagonist of the drug.
- the present invention relates to an oral dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutic agent and the second composition comprises an adverse-effect agent, wherein the second composition is coated with an inner acid-soluble layer and an outer base-soluble layer.
- the invention further relates to an oral dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutic agent and is coated with an inner base-soluble layer and an outer acid-soluble layer and the second composition comprises an adverse-effect agent and is coated with an inner acid-soluble layer and an outer base-soluble layer.
- the invention further relates to a method for treating or preventing pain, comprising administering to a patient in need thereof the oral dosage form of the invention.
- the method comprises administering to a patient in need thereof an oral dosage form comprising a first composition and a second composition, wherein the first composition comprises an effective amount of a therapeutic agent; the second composition comprises an effective amount of an adverse-effect agent; an effective amount of the therapeutic agent is released in the patient's small intestine; and less than an effective amount of the adverse-effect agent is released in the patient's gastrointestinal tract.
- the invention still further relates to a method for preparing an oral dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutic agent and the second composition comprises an adverse-effect agent, wherein the second composition is coated with an inner acid-soluble layer and an outer base-soluble layer, the method comprising the step of preparing the oral dosage form as set forth herein.
- the invention still further relates to a method for preparing an oral dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutic agent and is coated with an inner base-soluble layer and an outer acid-soluble layer and the second composition comprises an adverse-effect agent and is coated with an inner acid-soluble layer and an outer base-soluble layer, the method comprising the step of preparing the oral dosage form as set forth herein.
- Fig. 1 shows a cross-sectional view of a coated granule of a first composition useful in the oral dosage forms of the invention.
- Fig. 2 shows a cross-sectional view of a coated granule of a second composition useful in the oral dosage forms of the invention.
- Fig. 3 shows a cross-sectional view of a first embodiment of the invention, which is a capsule containing coated granules of a first composition and coated granules of a second composition.
- Fig. 4 shows a cross-sectional view of a second embodiment of the invention, which is a two-layer tablet.
- Fig. 5 shows a cross-sectional view of a third embodiment of the invention, which is a tablet containing coated granules of a first composition and coated granules of a second composition.
- Fig. 6 shows a cross-sectional view of a fourth embodiment of the invention, which is a coated tablet containing a first composition, with granules of a coated second composition dispersed throughout the first composition.
- Fig. 7 shows a cross-sectional view of a fifth embodiment of the invention, which is a tablet wherein a coated composition of the adverse-effect agent is further coated with the therapeutic agent and then the therapeutic agent is coated. 5.
- the oral dosage form of the present invention comprises a first composition and a second composition.
- the first composition comprises a therapeutic agent
- the second composition comprises an adverse-effect agent.
- therapeutic agent means any drug intended to have a beneficial effect when administered to a patient.
- the term "adverse-effect agent,” as used herein, means an agent that (A) reduces or eliminates one or more pharmacological effects of the therapeutic agent, such as a euphoric or toxic effect or (B) causes an undesired physiological reaction, such as emesis.
- the second composition is coated with a layer that is substantially insoluble in the gastrointestinal tract.
- both the first composition and second composition have a coating comprising at least two layers, an acid- soluble layer and a base-soluble layer, but the order of the layers in the coating on the first composition is different from that of the layers in the coating on the second composition.
- the coating covering the first composition comprises an outer acid-soluble layer and an inner base-soluble layer, which are dissolved when orally administered to a patient.
- the coating covering the second composition comprises an outer base-soluble layer, which gets dissolved when orally administered, and an inner acid-soluble layer, which does not get dissolved when orally administered to a patient.
- the oral dosage form When orally administered to a patient, the oral dosage form passes through the stomach first, where its acidic environment dissolves the first composition's outer acid- soluble layer, and then passes into the small intestine, where its basic environment dissolves the first composition's inner base-soluble layer.
- the therapeutic agent can be absorbed by the body.
- the second composition is coated with an outer base-soluble layer, which is substantially insoluble in the stomach's acidic environment. Therefore, the second composition passes through the stomach with both the outer base-soluble layer and the inner acid-soluble layer intact.
- the outer base-soluble layer dissolves, exposing the inner acid-soluble layer, which is substantially insoluble in the small intestine's basic environment, so that the adverse-effect agent cannot be absorbed by the body.
- the oral dosage form of the present invention is orally administered to a patient, for example a human, as intended, only the therapeutic agent is released in the gastrointestinal tract and absorbed by the patient; the adverse-effect agent is not released and, therefore, not available for absorption into the body.
- the therapeutic agent works as if it were administered alone without the adverse-effect agent, since only the therapeutic agent is available for absorption by the body.
- the oral dosage form of the present invention is tampered with, e.g., chewed, crushed, ground or dissolved, particularly in a solvent with heat (e.g., greater than about 45 °C to about 50°C), then not only the therapeutic agent but also the adverse- effect agent becomes available for absorption into the body.
- the adverse-effect agent can then exert its effect by either reducing the effect of the therapeutic agent or eliciting an unpleasant effect in the patient.
- the adverse-effect agent is an antagonist of the therapeutic agent, the effects of the therapeutic agent are drastically diminished or even eliminated by the effects of the adverse-effect agent.
- the opioid antagonist becomes bioavailable, interfering with opioid-receptor binding and reducing the opioid antagonist's pharmacological effects. Accordingly, only patients who take the dosage form of the present invention as intended, i.e, orally as an intact dosage form, can experience the full pharmacological effects of the therapeutic agent.
- the adverse-effect agent is an emetic agent and the oral dosage form is tampered with, the emetic agent induces vomiting which discourages the user from tampering with the dosage form.
- the oral dosage form of the invention not only discourages users from tampering with it, but can also be effective to remove the therapeutic agent from subject's body. Abusing the therapeutic agent becomes less desirable when present in the oral dosage form of the present invention because, when tampered with, the adverse-effect agent exerts its undesirable effects.
- the first composition is intended to be released slowly after it is orally administered to the subject. This prevents the burst, which some abusers seek.
- the first composition can be formulated as a slow release formulation, for example, by further coating the first composition with a sustained-release coating that slowly dissolves so that all the therapeutic agent is not released at once.
- the sustained-release coating is an innermost layer.
- the first composition can be formulated as a slow release formulation by incorporating the therapeutic agent into a matrix that slowly releases the therapeutic agent
- Therapeutic agents intended to be released slowly, when orally administered to a subject may have side effects if released all at once, rather than slowly.
- the coated second composition prevents tampering, which would result in immediate release of the therapeutic agent.
- Fig. 1 shows a cross-sectional view of an embodiment of the coated first
- composition 10 composition 10.
- a first composition 14 is covered with an innermost sustained-release coating 13 (optional), an inner base-soluble layer 12, and an outer acid-soluble layer 11.
- Fig. 2 shows a cross-sectional view of an embodiment of the coated second composition 20.
- a second composition 24 is covered with an inner acid-soluble layer 23, an outer base-soluble layer 22 and an outermost layer that is substantially insoluble in the -> gastrointestinal tract 21 (optional).
- any kind of therapeutic agent can be used in the oral dosage forms of the present invention.
- the oral dosage from is used in situations where there is
- useful therapeutic agents include, but are not limited to, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials,
- anti-migraine agents anti-muscarinic agents, anti-neoplastic agents, erectile-dysfunction- improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, ⁇ -blockers, cardiac ionotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastrointestinal agents, histamine receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents,
- the first composition can comprise more than one therapeutically active agent, leukotriene inhibitors, macrolides, muscle relaxants, nutritional agents, opioid analgesics, protease inhibitors, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, and non-essential fatty acids.
- the first composition can comprise more than one therapeutically active agent, and non-essential fatty acids.
- agent is also meant to encompass all pharmaceutically acceptable salts of the therapeutic agent.
- Pharmaceutically acceptable salts include, but are not limited to, metal salts, such as sodium salts, potassium salts, and lithium salts; alkaline earth metals, such as calcium salts, magnesium salts, and the like; organic amine salts, such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, and the like; inorganic acid salts such as hydrochloride salts, hydrobromide salts, sulfate salts, phosphate salts, and the like; organic acid salts such as formate salts, acetate salts, trifluoroacetate salts, maleate salts, tartrate salts, and the like; sulfonate salts such as methanesulfonate salts,
- the therapeutic agent has potential for abuse.
- the abuse potential of a drug is established by many factors, which may include the following: (1) the capacity of the drug to produce the kind of physical dependence in which drug withdrawal causes sufficient distress to bring about drug-seeking behavior; (2) the ability to suppress withdrawal symptoms caused by withdrawal from the drug; and (3) the degree to which the drug induces euphoria similar to that produced by morphine and other opioids.
- Opioids refers to a substance that binds, optionally stereo- specifically, to any of several subspecies of opioid receptors and produces an agonist action.
- Opioids include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine
- the opioid agonist is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymo ⁇ hone, bupreno ⁇ hine, fentanyl and derivatives thereof, dipipanone, heroin, tramadol, eto ⁇ hine, dihydroeto ⁇ hine, buto ⁇ hanol, levo ⁇ hanol, pharmaceutically acceptable salts thereof, and mixtures thereof.
- the opioid agonist is oxycodone or hydrocodone.
- benzodiazepines refers to drugs that are derivatives of benzodiazepine and are able to depress the central nervous system.
- Benzodiazepines include, but are not limited to, alprazolam, bromazepam, chlordiazepoxied, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, methylphenidate, pharmaceutically acceptable salts thereof, and mixture thereof.
- Barbiturates refer to sedative-hypnotic drugs derived from barbituric acid (2,
- Barbiturates include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, pharmaceutically acceptable salts thereof, and mixtures thereof.
- Stimulants refer to drugs that stimulate the central nervous system.
- Stimulants include, but are not limited to, amphetamines, such as amphetamine, amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate, pharmaceutically acceptable salts thereof and mixtures thereof.
- amphetamines such as amphetamine, amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate, pharmaceutically acceptable salts thereof and mixtures thereof.
- therapeutic agent having potential for abuse include, but are not limited to, dronabinol, glutethimide, methylphenidate, nabilone, anabolic steroids, methylprylon, ethchlorovynol, ethinamate, fenfluramine, meprobamate, pemoline, levomethadyl, benzphetamine, chlo ⁇ hentermine, diethylpropion, phentermine, mebutamate, chlortermine, phenylacetone, dronabinol, nabilone, benphetamine, chloral hydrate, ethclorovynol, paraldehyde, midazolam, and detropropoxyphene.
- the therapeutic agent may also be an agent intended for delivery to the colon.
- Therapeutic agents intended for delivery to the colon include, but are not limited to, agents that act locally in the colonic region to treat a colon diseases such as irritable bowel syndrome, irritable bowel disease, Crohns disease, constipation, post operative atony, gastrointestinal infections, and therapeutic agents that deliver antigenic material to the lymphoid tissue.
- Agents for the treatment of colon disease include, but are not limited to 5-ASA; steroids, such as hydrocortisone and budesonide; laxatives; octreotide; cisapride; anticholinergics; opioids; calcium channel blockers; DNA for delivery to the cells of the colon; glucosamine; thromboxane A 2 synthetase inhibitors, such as Ridogrel; 5HT3-antagonists, such as ondansetron; antibodies against infectious bacteria, such as Clostridium difficile; and antiviral agents, for example, for the prophylaxis of HIV.
- the therapeutic agent can be an agent that is systemically active and for which abso ⁇ tion is improved in the colon region.
- Such drugs include polar compounds such as: heparins; insulin; calcitonins; human growth hormone (HGH); growth hormone releasing hormone (GHRH); interferons; somatostatin and analogues such as octreotide and vapreotide; erythropoietin (EPO); granulocyte colony stimulating factor (GCSF); parathyroid hormone (PTH); luteinising hormone releasing hormone (LHRH) and analogues thereof; atrial natriuretic factor (ANF); vasopressin; desmopressin; calcitonin gene related peptide (CGRP); and analgesics.
- polar compounds such as: heparins; insulin; calcitonins; human growth hormone (HGH); growth hormone releasing hormone (GHRH); interferons; somatostatin and analogues such as octreotide and vapreotide; erythropoietin (EPO
- the adverse-effect agent can be an agent that reduces or eliminates the therapeutic agent's pharmacological activities including, but not limited to: (1) the capacity of the drug to produce the kind of physical dependence in which drug withdrawal causes sufficient distress to bring about drug-seeking behavior; (2) the ability to suppress withdrawal symptoms caused by withdrawal from the drug; and (3) the induction of euphoria similar to that produced by mo ⁇ hine and other opioids.
- Adverse-effect agents that reduce or eliminate the pharmacological effects of the therapeutic agent include, but are not limited to, antagonists of the therapeutic agent agonist. When an opioid agonist is used as the therapeutic agent in the oral dosage form of the present invention, an opioid antagonist can be used as the adverse-effect agent.
- a benzodiazepine antagonist when used as the therapeutic agent in the oral dosage form of the present invention, a benzodiazepine antagonist can be used as the adverse-effect agent.
- a barbiturate when used as a therapeutic agent in the oral dosage form of the present invention, a barbiturate antagonist can be used as the adverse-effect agent.
- an amphetamine when used as a therapeutic agent in the oral dosage form of the present invention, an amphetamine antagonist can be used as the adverse-effect agent.
- the therapeutic agent is toxic when dosed above its normal therapeutic range, i.e., there is a potential for an overdose, then an antidote of the toxic therapeutic agent can be used as the adverse-effect agent.
- compositions include, but are not limited to, metal salts, such as sodium salts, potassium salts, and lithium salts; alkaline earth metals, such as calcium salts, magnesium salts, and the like; organic amine salts, such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, and the like; inorganic acid salts such as hydrochloride salts, hydrobromide salts, sulfate salts, phosphate salts, and the like; organic acid salts such as formate salts, acetate salts, trifluoroacetate salts, maleate salts, tartrate salts, and the like; sulfonate salts such as methanesulfonate salts,
- Opioid antagonists that can be used as the adverse-effect agent of the present invention include, but are not limited to, naloxone, naltrexone, nalmefene, cyclazacine, levallo ⁇ han, and mixtures thereof.
- the opioid antagonist is naloxone or naltrexone.
- Benzodiazepine antagonists that can be used as the adverse-effect agent of the present invention include, but are not limited to, flumazenil.
- Barbiturate antagonist which can be used as the adverse-effect agent of the present invention include, but are not limited to, amphetamines, described herein.
- Stimulant antagonists that can be used as the adverse-effect agent of the present invention include, but are not limited to, benzodiazepines, described herein.
- the adverse-effect agent is an agent that causes an undesired physiological reaction, such as emesis.
- This type of adverse-effect agent can be used with any kind of therapeutic agent including an opioid, a benzodiazepine, a barbiturate, and a stimulant.
- emetic agents suitable for use as the adverse-effect agent in the present invention includes any drug that safely and effectively induces vomiting after administration including, but not limited to, ipecac and apomo ⁇ hine.
- Examples of useful coatings that are substantially insoluble in the gastrointestinal tract include, but are not limited to, coatings comprising a hydrophobic material.
- the coating that is substantially insoluble in the gastrointestinal tract comprises a cellulose polymer.
- the cellulose polymer is a cellulose ether, a cellulose ester, or a cellulose ester ether.
- the cellulose polymers have a degree of substitution, D.S., on the anhydroglucose unit of from zero up to and including 3.
- degree of substitution is meant the average number of hydroxyl groups present on the anhydroglucose unit of the cellulose polymer that are replaced by a substituting group.
- Representative cellulose polymers include, but are not limited to, polymers selected from cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono, di, and tricellulose alkanylates, mono, di, and tricellulose aroylates, and mono, di, and tricellulose alkenylates.
- Exemplary cellulose polymers include cellulose acetate having an acetyl content up to about 21%; cellulose acetate having an acetyl content up to about 32 to 39.8%; cellulose acetate having a D.S. of about 1 to 2 and an acetyl content of about 21 to 35%; and cellulose acetate having a D.S.
- the cellulose polymer is ethylcellulose, cellulose acetate, cellulose propionate (low, medium, or high molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, or cellulose triacetate.
- the ethylcellulose has an ethoxy content of about 44 to 55%.
- More specific cellulose polymers include cellulose propionate having a D.S. of about 1.8 and a propyl content of about 39.2 to 45% and a hydroxyl content of about 2.8 to 5.4%; cellulose acetate butyrate having a D.S. of about 1.8, an acetyl content of about 13 to 15%), and a butyryl content of about 34 to 39%; cellulose acetate butyrate having an acetyl content of about 2 to 29%, a butyryl content of about 17 to 53%, and a hydroxyl content of about 0.5 to 4.7%; cellulose triacylate having a D.S.
- cellulose diacylates having a D.S. of about 2.2 to 2.6 such as cellulose disuccinate, cellulose dipalmitate, cellulose dioctanoate, cellulose dipentanoate, and coesters of cellulose such as cellulose acetate butyrate, cellulose acetate octanoate butyrate, and cellulose acetate propionate.
- Additional cellulose polymers useful for coating the second composition with a coating that is substantially insoluble in the gastrointestinal tract include, but are not limited to, acetaldehyde dimethyl cellulose acetate, cellulose acetate ethylcarbamate, cellulose acetate methylcarbamate, and cellulose acetate dimethylaminocellulose acetate.
- Acrylic polymers are also useful for coating the second composition with a coating that is substantially insoluble in the gastrointestinal tract.
- Acrylic polymers include, but are not limited to, acrylic resins comprising copolymers synthesized from acrylic and methacrylic acid esters (e.g., the copolymer of acrylic acid lower alkyl ester and methacrylic acid lower alkyl ester) containing about 0.02 to 0.03 moles of a tri (lower alkyl) ammonium group per mole of acrylic and methacrylic monomer.
- the acrylic resin is Eudragit RS 30 D manufactured by Rohm Tech Inc. of Fitchburg, MA.
- Eudragit RS 30 D is a water insoluble copolymer of ethyl acrylate (EA), methyl methacrylate (MM) and trimethylammonioethyl methacrylate chloride (TAM) in which the molar ratio of TAM to the remaining components (EA and MM) is 1:40.
- Aqueous suspensions of acrylic resins such as EUDRAGIT RS can be used to coat the adverse-effect agent of the invention.
- the acrylic polymer is selected from acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylates, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymers, poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.
- a cellulose polymer or an acrylic polymer is used as a coating that is substantially insoluble in the gastrointestinal tract
- suitable plasticizers e.g., acetyl triethyl citrate and/or acetyl tributyl citrate
- the coating that is substantially insoluble in the gastrointestinal tract may also contain additives such as coloring agents, talc, and/or magnesium stearate, which are well known in the coating art.
- Polymers useful for coating the second composition with a coating that is substantially insoluble in the gastrointestinal tract also include, but not limited to, poly(lactic/glycolic acid) (“PLGA”) copolymers, polylactides, polyglycolides, polyanhydrides, polyorthoesters, polycaprolactones, polyphosphazenes, polysaccharides, proteinaceous polymers, polyesters, polydioxanone, polygluconate, polylactic-acid polyethylene oxide copolymers, poly(hydroxybutyrate), polyphosphoesters, and mixtures thereof.
- PLGA poly(lactic/glycolic acid)
- the polymer comprises a poly(lactic/glycolic acid) copolymer, a copolymer of lactic and glycolic acid, having a molecular weight of about 2,000 to about 500,000 daltons.
- the ratio of lactic acid to glycolic acid is from about 100:0 to about 25:75, in one embodiment from about 65:35.
- Poly(lactic/glycolic acid) maybe prepared by the procedure set forth in U.S. Patent No. 4,293,539 to Ludwig et al., the disclosure of which is expressly inco ⁇ orated herein by reference thereto.
- the coating that is substantially insoluble in the gastrointestinal tract is of sufficient thickness to prevent release of the adverse-effect agent from the second composition while it is in the gastrointestinal tract.
- Many of the coatings that are substantially insoluble in the gastrointestinal tract are slowly biodegraded or dissolved in an aqueous environment and, after sufficient time, will eventually release the adverse-effect agent. Accordingly, the coating should be of a sufficient thickness that does not permit the adverse effect agent to be released during the time that the adverse-effect agent is present in the gastrointestinal tract. The thickness of the coating will depend on the characteristics of the coating composition being used. 5.4.2 ACID-SOLUBLE LAYER
- the coating useful in the present invention comprises an acid-soluble layer.
- the term "acid-soluble layer” refers to a layer that is substantially soluble at a pH of less than about pH 5.0, but substantially insoluble at a pH of greater than about pH 5.5.
- the acid-soluble layer is substantially soluble at a pH of less than about pH 4.0, but substantially insoluble at a pH of greater than about pH 4.5.
- the acid-soluble layer is substantially soluble at a pH of less than about pH 3.0, but substantially insoluble at a pH of greater than about pH 3.5.
- the acid-soluble layer typically comprises an acid-soluble polymer.
- the phrase "substantially soluble,” when used to describe a layer, means soluble to a degree that a portion of that which the layer covers, for example, an acid-soluble layer, a base-soluble layer, a first composition, or a second composition, is made available to the environment of the gastrointestinal tract in an effective amount.
- the phrase "substantially insoluble,” when used to describe a layer, means that the layer does not dissolve or does so only to a degree that a portion of that which the layer covers, for example, an acid-soluble layer, a base-soluble layer, a first composition, or a second composition, is not made available to the environment of the gastrointestinal tract or is made available to the environment of the gastrointestinal tract in less than an effective amount.
- the acid-soluble polymer has a dimethylaminoethyl ammonium functionality.
- EUDRAGIT E 100 or Eudragit E PO from Rohm Pharma GmbH, Rothstat, Germany. Examples of other suitable acid-soluble polymers can be found in "Materials Used in Pharmaceutical Formulations," edited by A.T. Florence, Society of Chemical Industries, 1984.
- the coating of the present invention comprises a base-soluble layer.
- base-soluble layer refers to a layer that is substantially soluble at a pH of greater than about pH 5.5, but substantially insoluble at a pH of less than about 5.0.
- the base-soluble layer is substantially soluble at a pH of greater than about pH 6.5, but substantially insoluble at a pH of less than about 6.0.
- the base-soluble layer is substantially soluble at a pH of greater than about pH 7.5, but substantially insoluble at a pH of less than about 7.0.
- the base-soluble layer generally comprises a base-soluble polymer.
- the base-soluble polymer is an anionic copolymer of methacrylic acid and methacrylates having carboxylic acid functionalities.
- a polymer is commercially available as EUDRAGIT L 100-55, EUDRAGIT L 30D-55, EUDRAGIT L, or EUDRAGIT S 100 (commercially available from Rohm Pharma GmbH, Rothstat, Germany).
- EUDRAGIT L 100-55 is commercially available as EUDRAGIT L 100-55, EUDRAGIT L 30D-55, EUDRAGIT L, or EUDRAGIT S 100 (commercially available from Rohm Pharma GmbH,mannstat, Germany).
- EUDRAGIT S 100 commercially available from Rohm Pharma GmbH, Rothstat, Germany.
- Examples of other suitable base-soluble polymers can be found in "Materials Used in Pharmaceutical Formulations," edited by A.T. Florence, Society of Chemical Industries, 1984.
- the therapeutic agent is released slowly over time.
- Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the oral dosage forms of the invention.
- Single unit dosage forms suitable for oral administration, such as tablets, capsules, gelcaps, caplets, and the like, that are adapted for controlled-release are encompassed by the present invention.
- controlled release of the therapeutic agent from the first composition can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds.
- the controlled release of the therapeutic agent can be achieved, for example by coating or admixing the therapeutic agent with a controlled- release component.
- controlled-release component in the context of the present invention is defined herein as a compound or mixture of compounds, including polymers, polymer matrices, gels, permeable membranes, liposomes, microspheres, or the like, or a combination thereof, that facilitates the controlled-release of the therapeutic agent from the first composition of the oral dosage form of the invention.
- the therapeutic agent is formulated for controlled release by coating the therapeutic agent with a sustained- release coating.
- sustained-release coating refers to a coating made of one or more materials that allows for the slow release of the drug over time.
- the sustained-release coating is a pH-independent layer, i.e., a coating that has a defined permeability that is not influenced by pH.
- pH-independent layer means that the difference, at any given time, between the amount of drug released at, e.g., pH 1.6, and the amount released at any other pH, e.g., pH 7.2, when measured using a specific method, such as, for example, the USP Paddle Method at 100 ⁇ ra in 900 ml aqueous buffer, is 10% (by weight) or less.
- sustained-release coating Any sustained-release coating known to those of ordinary skill in the art can be used in the oral dosage form of the invention.
- Sustained-release coatings are well known in the art (See, e.g., Remingtons Pharmaceutical Sciences, 18 th ed. Mack Publishing Co., Easton, PA, 1990, p. 1670).
- the sustained-release coating comprises a water- insoluble material, such as a wax or a wax-like substance, fatty alcohol, shellac, zein, hydrogenated vegetable oil, water insoluble cellulose, polymer of acrylic and/or methacrylic acid, or any other slowly digestible or dissolvable solid known in the art.
- the coating formulations useful in the present invention should be capable of producing a strong, continuous film that is smooth and elegant, capable of supporting pigments and other coating additives, non-toxic, inert, and tack-free.
- the film coat is applied to the first composition, for example when in the form of a tablet or a granule, to achieve a weight gain level from about 2 to about 25 percent.
- the film coat may be lesser or greater depending upon the physical properties of the therapeutic agent included in the formulation o and the desired release rate.
- the sustained-release coating comprises a hydrophobic polymer.
- the hydrophobic polymer comprises a water-insoluble cellulosic polymer, such as an alkylcellulose, for example ethylcellulose; an acrylic polymer; or mixtures thereof.
- the sustained-release coating comprises an acrylic polymer. Any acrylic polymer that is pharmaceutically acceptable can be used.
- the acrylic polymer can be an acrylate or methacrylate, formed from one or more of acrylic acid, methacrylic acid, acrylic acid esters, and methacrylic acid esters.
- acrylic polymers can be cationic, anionic, or non-ionic, so that it is possible to obtain polymers that 0 are soluble in, or resistant to dissolution, over a wide range of pH values.
- Some acrylic polymers useful for the piuposes of the present invention are those that are marketed under the trade name EUDRAGIT (commercially available from Rohm Pharma GmbH, Rothstat, Germany).
- acrylic polymers include, but are not limited to, acrylic acid and methacrylic acid copolymers, methyl methacrylate polymers, methyl 5 methacrylate copolymers, ethoxyethyl methacrylates polymers, cyanoethyl methacrylate polymers, aminoalkyl methacrylate copolymers, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamine copolymers, poly(methyl methacrylate), poly(methacrylic acid)(anhydride), polymethacrylate, polyacrylamide, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.
- the acrylic polymer can comprise one or more ammonio methacrylate copolymers.
- Ammonio methacrylate copolymers are well known in the art, and are fully polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.
- polymers suitable for use in the invention include, but are not limited to, hydroxyalkylcelluloses; poly(lactic/glycolic acid) ("PLGA”); polylactide; polyglycolide; polyanhydrides; polyorthoesters; polycaprolactone; polyphosphazenes; polysaccharides; proteinaceous polymers; polyesters; polydioxanone; polygluconate; polylactic-acid polyethylene oxide copolymers; poly(hydroxybutyrate) polyphosphoesters; or mixtures thereof.
- PLGA poly(lactic/glycolic acid)
- polylactide polyglycolide
- polyanhydrides polyorthoesters
- polycaprolactone polyphosphazenes
- polysaccharides proteinaceous polymers
- polyesters polydioxanone
- polygluconate polylactic-acid polyethylene oxide copolymers
- poly(hydroxybutyrate) polyphosphoesters or mixtures thereof.
- the inclusion of an effective amount of a plasticizer in the aqueous dispersion of hydrophobic polymer can further improve the physical properties of the film.
- ethylcellulose has a relatively high glass-transition temperature (“Tg") and does not form flexible films under normal coating conditions, it is often necessary to plasticize the ethylcellulose before using it as a coating material.
- Tg glass-transition temperature
- the suitability of a plasticizer may relate to its affinity or solvating power for the polymer and its effectiveness for interfering with polymer-polymer attachments. Such activity imparts a desired flexibility to the polymer by relieving molecular rigidity.
- An important parameter in determining the suitability of a plasticizer for a polymer is related to the Tg of the polymer.
- the Tg is related to the temperature or temperature range where there is a fundamental change in the physical properties of the polymer. This change does not reflect a change in state, but rather a change in the macromolecular mobility of the polymer.
- the Tg is above room temperature, the polymer will behave as a glass at room temperature, being hard, non-pliable, and rather brittle: properties that are restrictive for a film coating since the coated dosage form maybe subjected to a certain amount of external stress.
- suitable plasticizers into the polymer matrix effectively reduces the Tg, so that under ambient conditions the films are softer, more pliable and often stronger, and, thus, better able to resist mechanical stress.
- Other aspects of suitable plasticizers include their ability to act as a good "swelling agent," especially for ethylcellulose, and to improve the solubility profile of the coating in water.
- plasticizers for ethylcellulose include dibutyl sebacate, diethyl phthalate, triethyl citrate, and tributyl citrate, although other plasticizers (such as acetylated monoglycerides, phthalate esters and castor oil) can be used.
- triethyl citrate is a plasticizer for the aqueous dispersions of ethyl cellulose.
- suitable plasticizers for the acrylic polymers useful in the present invention include, but are not limited to, citric acid esters such as triethyl citrate, tributyl citrate, dibutyl phthalate, and 1,2-propylene glycol.
- lacquer solutions include polyethylene glycols, propylene glycol, diethyl phthalate, castor oil, and triacetin.
- the plasticizer is typically added to a solution of the polymer in an aqueous or non-aqueous solvent that is used to coat the first composition.
- the amount of plasticizer included in a coating solution is based on the concentration of the coating. In one embodiment, the amount of plasticizer included
- a coating solution of ethylcellulose is from about 1 to about 50 percent by weight of the ethylcellulose.
- the amount of plasticizer included in a coating solution of an aqueous dispersion of acrylic polymer is about 20%.
- the necessary concentration of the plasticizer for a particular coating solution and method of application can be readily determined by one of ordinary skill in the art without undue experimentation.
- a commercially available aqueous dispersion of ethylcellulose suitable for use in the invention is AQUACOAT (commercially available from FMC Co ⁇ ., Philadelphia, Pa., U.S.A.).
- AQUACOAT is prepared by dissolving ethylcellulose in a water-immiscible organic solvent and then emulsifying the organic solvent in water in the presence of a surfactant and a stabilizer. After homogenization to generate submicron
- the organic solvent is evaporated under vacuum to form a pseudolatex.
- Plasticizer is not inco ⁇ orated in the pseudolatex during the manufacturing phase; therefore, prior to using the pseudolatex as a coating, it is necessary to intimately mix the AQUACOAT with a suitable plasticizer.
- SURELEASE commercially available from Colorcon, Inc., West Point, Pa., U.S.A.
- the acrylic coating comprises an acrylic resin lacquer used in the form of an aqueous dispersion, such as EUDRAGIT.
- the acrylic coating comprises a mixture of two acrylic resin lacquers commercially available
- EUDRAGIT RL 30 D and EUDRAGIT RS 30 D are copolymers of acrylic and methacrylic esters having a low content of quaternary ammonium groups, the molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters being 1 :20 in EUDRAGIT RL 30 D and 1 :40 in EUDRAGIT RS 30 D.
- the mean molecular weight of these materials is about
- EUDRAGIT RL/RS mixtures are substantially insoluble in water and in digestive fluids. However, coatings formed from the same are swellable and permeable in aqueous solutions and digestive fluids.
- the EUDRAGIT RL/RS dispersions useful in the present invention can be mixed together in any desired ratio in order to ultimately obtain a controlled-release formulation having a desirable dissolution profile.
- Desirable controlled-release formulations can be obtained, for instance, from a coating derived from 100% EUDRAGIT RL; 50%EUDRAGIT RL, 50% EUDRAGIT RS; and 10% EUDRAGIT RL, 90% Eudragit RS (each commercially available from Rohm Pharma GmbH,mannstat, Germany).
- the sustained-release coating can also comprise a mixture of a hydrophobic material and a hydrophilic material.
- the ratio of hydrophobic material to hydrophilic material is determined by, among other factors, the required release rate of the therapeutic agent and the solubility characteristics of the materials selected.
- Hydrophilic materials include, but are not limited to, polyvinylpyrrolidone and water soluble celluloses, such as hydroxypropylmethyl cellulose. Examples of combinations of hydrophobic material and hydrophilic material useful for the sustained-release coating include, but are not limited, to a combination of shellac and polyvinylpyrrolidone and a combination of ethyl cellulose and hydroxypropylmethyl cellulose.
- controlled-release matrix means a matrix that slowly releases the therapeutic agent over time. Any controlled-release matrix can be used in the oral dosage form of the invention.
- Certain controlled-release matrices are known for oral formulations (See, e.g., Remingtons Pharmaceutical Sciences, 18 th ed. Mack Publishing Co., Easton, PA, 1990, p. 1684-1685). Other examples of useful controlled-release matrices are described in U.S. Patent Nos.
- the controlled-release matrix can be a fusible hydrophobic material, optionally combined with a hydrophilic material.
- the hydrophobic fusible material can be, for example, a hydrophobic polymer or a natural or synthetic wax or oil, such as hydrogenated vegetable oil or hydrogenated castor oil, which in one embodiment has a melting point of from about 35 to 100°C, and in another embodiment from about 45 to 90°C.
- the hydrophilic material can be a hydrophilic polymer; a water soluble fusible material, such as polyethylene glycol; or a water soluble particulate material, such as dicalcium phosphate or lactose.
- the therapeutic agent dispersed in a controlled-release matrix can be prepared by formulating, e.g. , using dry or wet granulation or by blending, the therapeutic
- Suitable non-fusible materials for inclusion in a controlled release matrix include, but are not limited to:
- hydrophilic or hydrophobic polymers such as gums, cellulose ethers, protein-derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, starches, polyvinylpyrrolidones, and cellulose acetate phthalate.
- cellulose ethers such as gums, cellulose ethers, protein-derived materials, nylon, acrylic resins, polylactic acid, polyvinylchloride, starches, polyvinylpyrrolidones, and cellulose acetate phthalate.
- acrylic resins such as polylactic acid, polyvinylchloride, starches, polyvinylpyrrolidones, and cellulose acetate phthalate.
- ethers for example substituted cellulose ethers such as alkylcelluloses (e.g., ethylcellulose), C, - C 6 hydroxyalkylcelluloses (e.g., hydroxypropylcellulose and hydroxyethyl cellulose), and acrylic resins (e.g., methacrylates such as methacrylic acid copolymers) are used in one embodiment.
- the controlled-release matrix can conveniently contain between 1% and 80% (by weight) of the hydrophobic and or hydrophilic polymer.
- digestible, long chain (C 8 - C 50 , in one embodiment C 8 - C 40 ) substituted or unsubstituted hydrocarbons such as fatty acids; hydrogenated vegetable oils; fatty alcohols, such as lauryl, myristyl, stearyl, cetyl or, in one embodiment cetostearyl alcohol; glyceryl esters of fatty acids, for example, glyceryl monostearate; mineral oils; and waxes, such as beeswax, glycowax, castor wax, and carnauba wax.
- Hydrocarbons having a melting such as fatty acids; hydrogenated vegetable oils; fatty alcohols, such as lauryl, myristyl, stearyl, cetyl or, in one embodiment cetostearyl alcohol; glyceryl esters of fatty acids, for example, glyceryl monostearate; mineral oils; and waxes, such as beeswax, glycowax, castor wax, and carn
- the controlled-release matrix may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
- the controlled-release matrix may contain up to
- a suitable controlled-release matrix for use in the oral dosage form of the invention comprises one or more cellulose ethers or acrylic resins, one or more C 12 - C 36 , in one embodiment C 12 - C 22 , aliphatic alcohols, and/or one or more hydrogenated vegetable oils.
- a particular suitable matrix comprises one or more alkylcelluloses, one or more
- C 12 - C 36 in one embodiment C 12 - C 22 , aliphatic alcohols, and optionally one or more polyalkylene glycols.
- the matrix contains between about 0.5% and 60%), and in another embodiment, between 1% and 50% (by weight) of the cellulose ether.
- the acrylic resin is for example a methacrylate such as methacrylic acid copolymer USNF Type A (EUDRAGIT L), Type B (EUDRAGIT S,), Type C (EUDRAGIT
- EUDRAGIT NE 30 D contains between about 0.5% and 60% by weight, and in another embodiment between 1% and 50% by weight of the acrylic resin.
- the matrix in one embodiment contains between about 1% and 40%, in another embodiment between about 2% and 36% (by weight) of the aliphatic alcohol.
- the combined weight of the aliphatic alcohol and the polyalkylene glycol in one embodiment constitutes between about 2% and 40%, in another embodiment between about 2 and 36% (by weight) of the matrix.
- the polyalkylene glycol may be, for example, polypropylene glycol or, in one embodiment, polyethylene glycol.
- the number average molecular weight of the at least one polyalkylene glycol is in one embodiment between 200 and 15,000, and in another embodiment between 400 and 12,000.
- the controlled-release matrix containing the therapeutic agent can readily be prepared by dispersing the therapeutic agent in the components of the matrix using conventional pharmaceutical techniques including, but not limited to, melt granulation, wet granulation, dry blending, dry granulation, and co-precipitation.
- the controlled-release formulations slowly release the therapeutic agent when ingested and exposed to gastric and/or intestinal fluids.
- the first and second compositions are solids, such as, but not limited to, granules, fine granules, pills, beads, capsules, tablets, or powders. Methods for preparing these solids are well known in the art.
- the compositions can additionally comprise any conventional pharmaceutically acceptable excipient such as a binding agent i e -g-- > pregelatmised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); filler (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricant (e.g., magnesium stearate, talc or silica); disintegrant (e.g., potato starch or sodium starch glycolate); or wetting agent (e.g., sodium lauryl sulphate).
- a binding agent i e -g-- > pregelatmised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose filler (e
- compositions can also contain a minor amount of an emulsifying agent or a pH-buffering agent.
- the first and/or second composition comprises a hydrophobic material to provide the composition with a sustained-release property. Examples of useful hydrophobic material are disclosed in section 5.4.4, supra.
- Solid compositions can be prepared by using conventional methods known in the art, for example, wet granulation, melt extrusion, and tableting by compression. The solid compositions are coated with layers by applying one or more coating mixtures.
- Coating mixtures are prepared by any conventional means, for example, by dissolving the above-mentioned polymers and optionally plasticizers in a suitable solvent or mixture of solvents, for example water, methanol, ethanol, isopropanol, acetone, ethylacetate, ethylene chloride, or mixtures thereof.
- suitable solvent or mixture of solvents for example water, methanol, ethanol, isopropanol, acetone, ethylacetate, ethylene chloride, or mixtures thereof.
- plasticizers include, but are not limited to, citric acid esters, such as triethyl citrate and tributyl citrate; dibutyl phthalate; 1,2-propylene glycol; polyethylene glycols; castor oil; and triacetin.
- the coating mixture is an aqueous dispersion
- a small amount of talc, glyceral monostearate, or colloidal silicon dixide may be added to reduce the tendency of the aqueous dispersion to stick during processing.
- the coating mixture can also contain additives such as coloring agents and/or magnesium stearate, which are well known in the coating art.
- the coating solution can be applied to the solid composition by any means available to those of ordinary skill in the art such as, for example, spraying or dipping. Conventional coating apparatuses, well known to those of ordinary skill in the art, can be used to coat the solid composition (See, e.g., Remingtons Pharmaceutical Sciences, 18 th ed. Mack Publishing Co., Easton, PA, 1990).
- Conventional coating apparatuses include, but are not limited to, coating-granulating apparatuses of the centrifugal fluidized type, pan- coating apparatuses, and fluidized-bed granulating coating apparatuses.
- a Wuster fluidized-bed system can be used in which an air jet, injected from underneath, fluidizes the coated material and effects drying while the polymer coating is sprayed on.
- the first coating solution is applied and then allowed to dry before the second coating solution is applied.
- the coating solutions are applied to provide a dosage form that has a dissolution profile substantially unaffected by exposure to accelerated-storage conditions.
- accelerated-storage conditions means storage conditions of elevated temperature and/or elevated relative humidity to which the oral dosage form is subjected for the pu ⁇ ose of obtaining regulatory approval, e.g., the FDA for approval in the U.S., and an expiration date.
- regulatory approval e.g., the FDA for approval in the U.S.
- an expiration date e.g., a generally accepted test employed in FDA guidelines relates to the storage of a drug product (i.e., in its container and package) at 40° C and 75% Relative Humidity (RH). The length of time that the drug product can be stored under these conditions without chemically degrading and with its dissolution and physical characteristics remaining unchanged, is used to determine the expiration date of the drug product.
- RH Relative Humidity
- the amount of the therapeutic agent per dosage unit is that which is an effective amount for its particular indication and is independent of the amount of the adverse-effect agent.
- the amount of the opioid agonist in the oral dosage form of the present invention is generally from about 75 ng to about 1000 mg, in one embodiment from about 75 ng to about 750 mg.
- One of ordinary skill in the art can readily determine, without undue experimentation, the amount of therapeutic agent needed for a particular indication.
- the amount of the adverse-effect agent in the oral dosage form of the present invention is such that the adverse-effect agent can give the intended adverse effect.
- the amount of the adverse-effect agent in the oral dosage form is at least sufficient to reduce or eliminate the effects of the therapeutic agent when both agents are released.
- the phrase "to reduce or eliminate the effects of the therapeutic agent,” as used herein, means that the effects of the therapeutic agent that attract potential abusers are eliminated or become lessened.
- an adverse-effect agent can reduce the euphoric effect of a therapeutic agent.
- the amount of the opioid antagonist, present in a oral dosage form of the present invention can be from about 10 ng to 275 mg.
- the amount of the adverse-effect agent in the oral dosage form is at least sufficient to cause such effect upon release.
- the amount of the adverse-effect agent present in the oral dosage form should not be harmful to humans even if fully released.
- One of ordinary skill in the art can readily determine, without undue experimentation, the amount of adverse-effect agent needed to elicit the intended adverse-effect without being harmful.
- the ratio of the therapeutic agent to the adverse-effect agent in the oral dosage form is about 1 : 1 to about 50: 1 by weight, in one embodiment about 1:1 to about 20:1 by weight. In certain other embodiments, the ratio is about 1 :1 to about 10:1 by weight.
- the therapeutic agent includes oxycodone or hydrocodone and is present in the amount of about 15-45 mg, and the adverse-effect agent includes naltrexone and is present in about 0.5-5 mg.
- the first composition has a sustained-release coating, the therapeutic agent is an opioid agonist and the adverse-effect agent is an opioid antagonist.
- the sustained- release oral dosage forms can include analgesic doses from about 5 mg to about 80 mg of hydrocodone per dosage unit.
- the opioid agonist is hydromo ⁇ hone
- it may be included in an amount from about 2 mg to about 64 mg hydromo ⁇ hone hydrochloride per dosage unit.
- the opioid agonist is mo ⁇ hine
- the oral dosage forms of the present invention include from about 2.5 mg to about 800 mg mo ⁇ hine per dosage unit.
- the opioid agonist is oxycodone and the oral dosage forms include from about 2.5 mg to about 800 mg oxycodone, in another embodiment from about 20 mg to about 30 mg oxycodone per dosage unit.
- Controlled-release oxycodone formulations are known in the art.
- the opioid agonist can be tramadol in an amount from about 25 mg to 800 mg tramadol per dosage unit.
- the dosage form can contain more than one opioid agonist.
- the first composition and the second composition are coated as explained in section 5.4, supra to provide the first coated composition and the second coated composition.
- the first composition comprising a therapeutic agent
- the second composition comprising an adverse-effect agent
- the first composition and the second composition are then combined to provide a unit dosage of the oral composition of the invention.
- the first composition and the second composition are similar in their size, shape and color so that they cannot be readily distinguished from each other.
- the first composition and the second composition can each be powders, granules, or beads that are combined and inco ⁇ orated into a capsule or tablet using methods well known to those of ordinary skill in the art.
- the capsule may be hard or soft, for example, gelatin.
- the capsule can also contain pharmaceutically acceptable excipients.
- Fig. 3 shows a cross-sectional view of a capsule 30, which has a first part 33 and a second part 34 and contains powders, granules, or beads of a first composition 31 and powders or granules of a second composition 32.
- Fig. 5 shows a cross-sectional view of a dosage form according to the invention in the form of a tablet 50.
- the first composition is in the form of powders or granules 51 and the coated second composition is in the form of powders, granules, or beads 52.
- the first composition and the coated second composition are mixed with a pharmaceutically acceptable matrix 53 and compressed into a tablet.
- the capsule or tablet contains the first composition without the outer acid-soluble layer and without the inner base-soluble layer and the second composition coated with an outer base-soluble layer and an inner acid-soluble layer.
- Fig. 6 Depicts another embodiment of the oral dosage form of the invention in the form of a tablet comprising a core that is a mixture of an uncoated first composition 64 and a second composition coated with a base-soluble outer layer and an acid soluble inner layer 65. The core is then coated with an inner base-soluble layer 62, and an outer acid-soluble layer 61, and an optional innermost sustained release coating 63.
- the second composition can be coated with a layer that is substantially insoluble in the gastrointestinal tract.
- Another embodiment of the oral dosage form of the invention is a two-layer tablet 40 as shown in Fig. 4.
- a solid nucleus of the first composition 45 is covered with an innermost sustained-release coating 43 (optional), an inner base-soluble layer 42, and an outer acid-soluble layer 41.
- a solid nucleus of the second composition 44 is covered with an inner acid-soluble layer 46, an outer base-soluble layer 47, and an outermost layer that is substantially insoluble in the gastrointestinal tract 48 (optional).
- the two coated nuclei are then compressed into a two-layer tablet 40 using conventional tableting equipment and standard techniques to provide a two-layered tablet.
- the compressed two-layer tablet can then optionally be coated with an additional coating to provide a tablet of uniform appearance.
- the additional coating is a coating that dissolves in the stomach after the tablet is swallowed.
- the first composition is uncoated, i.e., is not covered with the outer acid-soluble layer or the inner base-soluble layer, but the second composition is coated with an outer base-soluble layer and an inner acid-soluble layer.
- FIG.7 Yet another embodiment of the oral dosage 70 is shown in Fig.7.
- a solid nucleus of the second composition 77 is coated with an innermost acid-soluble layer 76 and an outer base-soluble layer 75.
- the second composition is further coated with a layer of the first composition 74, an optional innermost pH-independent layer 73, an inner base- soluble layer 72, and an outer acid-soluble layer 71.
- the oral dosage 70 may be a tablet or a granule.
- EUDRAGIT RS 30 D is plasticized by mixing with triacetin. The dispersion is then combined with the oxycodone HC1 or naltrexene HC1, spray dried lactose, and providone using a fluid-bed granulator. The resulting mixture is granulated. If necessary the granules are dried. The granules are then screened with a sieve to provide granules of an appropriate size.
- An acid-soluble coating solution is prepared by dispersing 15.0 g EUDRAGIT El 00 in 200 ml of ethanol to provide a clear solution, and 4 g of the plasticizer triethyl citrate is added to the solution.
- a base-soluble coating solution is prepared by dispersing 15.0 g EUDRAGIT L in 200 ml of ethanol to provide a clear solution.
- the oxycodone HC1 granules are spray coated with the base-soluble coating solution and dried. After drying, the resulting oxycodone HC1 granules coated with the base-soluble coating are then spray coated with the acid-soluble coating solution and the resulting granules dried.
- the naltrexone HC1 granules are spray coated with the acid-soluble coating solution and dried. After drying, the resulting naltrexone HC1 granules coated with the acid-soluble coating are then spray coated with the base-soluble coating solution and the resulting granules dried.
- Stearyl alcohol is melted, and the melted stearyl alcohol (25.00 mg per unit) is mixed with the coated granules obtained in Example 1 to wax them.
- the waxed granules are cooled in a fluid bed dryer and then blended with talc (2.50 mg per unit) and magnesium stearate (1.25 mg per unit) to provide a blend.
- the resulting blend is compressed into a tablet using a tablet press.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02761250.6T DK1414459T3 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and a damaging agent |
EP02761250A EP1414459B1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
HU0401066A HUP0401066A2 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent and process for its preparation |
JP2003518547A JP5143995B2 (en) | 2001-08-06 | 2002-08-05 | Oral preparations containing therapeutic and adverse agents |
DE60234604T DE60234604D1 (en) | 2001-08-06 | 2002-08-05 | ORAL DOSAGE FORM CONTAINS A THERAPEUTIC AGENT AND AN ACTIVE ACTIVE SUBSTANCE |
DE20220838U DE20220838U1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form containing a therapeutic agent and a counteracting agent |
BR0211781-9A BR0211781A (en) | 2001-08-06 | 2002-08-05 | Oral dosage form, and methods for treating or preventing pain, and for preparing oral dosage form |
CA2456601A CA2456601C (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
KR1020047001854A KR100893895B1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
MXPA04001098A MXPA04001098A (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent. |
SI200230884T SI1414459T1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
IL16019502A IL160195A0 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
AT02761250T ATE450259T1 (en) | 2001-08-06 | 2002-08-05 | ORAL DOSAGE FORM CONTAINING A THERAPEUTIC ACTIVE INGREDIENT AND AN COUNTERACTIVE ACTIVE INGREDIENT |
HK04108654.6A HK1067524A1 (en) | 2001-08-06 | 2004-11-03 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30979101P | 2001-08-06 | 2001-08-06 | |
US60/309,791 | 2001-08-06 | ||
US10/000,000 | 2002-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003013538A1 true WO2003013538A1 (en) | 2003-02-20 |
Family
ID=23199688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024889 WO2003013538A1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Country Status (19)
Country | Link |
---|---|
US (3) | US20030044458A1 (en) |
EP (1) | EP1414459B1 (en) |
JP (3) | JP5143995B2 (en) |
KR (2) | KR20090005247A (en) |
AT (1) | ATE450259T1 (en) |
AU (1) | AU2008202531A1 (en) |
BR (1) | BR0211781A (en) |
CA (1) | CA2456601C (en) |
CY (1) | CY1109816T1 (en) |
DE (1) | DE20220838U1 (en) |
DK (1) | DK1414459T3 (en) |
ES (1) | ES2337664T3 (en) |
HK (1) | HK1067524A1 (en) |
HU (1) | HUP0401066A2 (en) |
MX (1) | MXPA04001098A (en) |
PT (1) | PT1414459E (en) |
RU (1) | RU2004106620A (en) |
SI (1) | SI1414459T1 (en) |
WO (1) | WO2003013538A1 (en) |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004037230A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form that is safeguarded from abuse |
EP1581188A1 (en) * | 2003-01-10 | 2005-10-05 | Mutual Pharmaceutical Company, Inc. | Pharmaceutical safety dosage forms |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
JP2006524261A (en) * | 2003-04-21 | 2006-10-26 | ユーロ−セルティーク エス.エイ. | Anti-modified dosage form containing coextrusion adverse agent particles and process for producing the same |
WO2006133733A1 (en) * | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
WO2007013975A2 (en) * | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
WO2007070632A2 (en) * | 2005-12-13 | 2007-06-21 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
JP2007517912A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ, インコーポレイテッド | Controlled release CGRP delivery composition for cardiovascular and renal indications |
JP2007517913A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ, インコーポレイテッド | Method for treating acute myocardial infarction by administering calcitonin gene-related peptide and composition containing calcitonin gene-related peptide |
EP1809259A2 (en) * | 2004-10-15 | 2007-07-25 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
EP1893183A1 (en) * | 2005-06-13 | 2008-03-05 | Paul Rosenberg | Emetic embedded capsule |
ITFI20100047A1 (en) * | 2010-03-24 | 2011-09-25 | Molteni & C | PHARMACEUTICAL FORMULATIONS BISTRATO CONTAINING OPPOSING AGONISTS AND ANTAGONISTS. |
EP2422775A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
US8298579B2 (en) | 2004-03-30 | 2012-10-30 | Euro-Celtique S.A. | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8383842B2 (en) | 2004-11-22 | 2013-02-26 | Purdue Pharma L.P. | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol |
US8445023B2 (en) | 2005-11-10 | 2013-05-21 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
US8691270B2 (en) | 2007-12-17 | 2014-04-08 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
WO2014059512A1 (en) * | 2012-10-15 | 2014-04-24 | Isa Odidi | Oral drug delivery formulations |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8877232B2 (en) | 2003-06-20 | 2014-11-04 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
US8927013B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
US8936808B1 (en) | 1997-12-22 | 2015-01-20 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9060950B2 (en) | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
US9585893B2 (en) | 2011-02-23 | 2017-03-07 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
US9597288B2 (en) | 2006-07-21 | 2017-03-21 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US9744157B2 (en) | 2011-05-10 | 2017-08-29 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9814684B2 (en) | 2002-04-09 | 2017-11-14 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US9820982B2 (en) | 2001-07-06 | 2017-11-21 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US9968556B2 (en) | 2010-04-01 | 2018-05-15 | Theravida, Inc. | Pharmaceutical formulations |
US10046032B2 (en) | 2016-03-24 | 2018-08-14 | Nutrinia, Ltd. | Use of insulin for promoting gastric emptying |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10328057B2 (en) | 2016-01-20 | 2019-06-25 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
WO2019173062A1 (en) * | 2018-03-07 | 2019-09-12 | Trucapsol, Llc | Reduced permeability microcapsules |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11344502B1 (en) | 2018-03-29 | 2022-05-31 | Trucapsol Llc | Vitamin delivery particle |
US11465117B2 (en) | 2020-01-30 | 2022-10-11 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11542392B1 (en) | 2019-04-18 | 2023-01-03 | Trucapsol Llc | Multifunctional particle additive for enhancement of toughness and degradation in biodegradable polymers |
US11571674B1 (en) | 2019-03-28 | 2023-02-07 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11794161B1 (en) | 2018-11-21 | 2023-10-24 | Trucapsol, Llc | Reduced permeability microcapsules |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US11878280B2 (en) | 2022-04-19 | 2024-01-23 | Trucapsol Llc | Microcapsules comprising natural materials |
US11904288B1 (en) | 2023-02-13 | 2024-02-20 | Trucapsol Llc | Environmentally biodegradable microcapsules |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
CN1592609A (en) * | 2001-05-11 | 2005-03-09 | 恩德制药公司 | Abuse-resistant opioid dosage form |
PL207748B1 (en) * | 2001-07-06 | 2011-01-31 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
JP2005523876A (en) * | 2001-09-26 | 2005-08-11 | ペンウェスト ファーマシューティカルズ カンパニー | Opioid formulations with reduced potential for abuse |
WO2003090717A1 (en) * | 2002-04-23 | 2003-11-06 | Nanotherapeutics, Inc | Process of forming and modifying particles and compositions produced thereby |
US20050186139A1 (en) * | 2002-10-25 | 2005-08-25 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10250084A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US8778382B2 (en) * | 2003-04-30 | 2014-07-15 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
JP4939217B2 (en) * | 2003-08-06 | 2012-05-23 | グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Abuse prevention dosage form |
US8075872B2 (en) * | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
CA2536816A1 (en) * | 2003-08-12 | 2005-03-03 | Endo Pharmaceuticals, Inc. | Method for deterring abuse of opioids by combination with non-release formulation of emetic |
US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US20050271594A1 (en) * | 2004-06-04 | 2005-12-08 | Groenewoud Pieter J | Abuse resistent pharmaceutical composition |
MXPA06014095A (en) * | 2004-06-04 | 2007-08-07 | Camurus Ab | Liquid depot formulations. |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DE102004032103A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
EP1817032A2 (en) * | 2004-11-29 | 2007-08-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
EP2319499A1 (en) * | 2005-01-28 | 2011-05-11 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
EP1863490A2 (en) * | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
DE502005006082D1 (en) * | 2005-09-26 | 2009-01-08 | Faber Castell Ag | Cosmetic liquid for coloring the nails and the skin |
FR2892937B1 (en) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING |
EP1810678A1 (en) † | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
SI2484346T1 (en) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
AU2007275034A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
SG10201503411QA (en) | 2006-08-03 | 2015-06-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
KR101445757B1 (en) * | 2006-08-04 | 2014-10-02 | 에씨팜 | Granule and orally disintegrating tablet comprising oxycodone |
WO2008024490A2 (en) * | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US8187636B2 (en) | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
WO2009032246A2 (en) | 2007-09-03 | 2009-03-12 | Nanotherapeutics, Inc. | Particulate compositions for delivery of poorly soluble drugs |
EP2042176A1 (en) * | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
US8802156B2 (en) * | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
EP3090743A1 (en) * | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
JP2011516412A (en) * | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス,エルエルシー | Compositions and methods for the treatment of cancer and mucositis |
WO2009114118A2 (en) * | 2008-03-08 | 2009-09-17 | Theraquest Biosciences, Inc. | Oral pharmaceutical compositions of buprenorphine and method of use |
RU2478388C2 (en) * | 2008-07-07 | 2013-04-10 | Еуро-Селтик С.А. | Pharmaceutical composition, containing opioid antagonist for treatment of urinary retention |
WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
US20110305658A1 (en) * | 2008-12-11 | 2011-12-15 | L'oreal S.A. | Lengthening mascara composition |
EP2379111B1 (en) * | 2008-12-12 | 2013-03-20 | Paladin Labs Inc. | Narcotic drug formulations with decreased abuse potential |
AU2010207740B2 (en) * | 2009-01-26 | 2016-06-16 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
US20110311631A1 (en) * | 2009-03-18 | 2011-12-22 | Evonik Röhm Gmbh | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
WO2011020030A2 (en) * | 2009-08-13 | 2011-02-17 | The General Hospital Corporation | Methods and compositions to prevent addiction |
EP3064064A1 (en) | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CN102821757B (en) * | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | By extrusion mechanism for powdery medicine compositions |
CN104873455B (en) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | Coated Tamper Resistant Controlled Release Dosage Forms |
US9233073B2 (en) | 2010-12-23 | 2016-01-12 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
EP2729148A4 (en) * | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Compositions and methods for treatment of symptoms in parkinson's disease patients |
SG2014009401A (en) | 2011-09-19 | 2014-05-29 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9763928B2 (en) * | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
WO2013128276A2 (en) * | 2012-03-02 | 2013-09-06 | Rhodes Pharmaceuticals L.P. | Tamper resistant immediate release formulations |
EA201491875A1 (en) | 2012-04-17 | 2015-04-30 | Пурдью Фарма Л.П. | SYSTEMS AND METHODS OF TREATMENT OF OPIOID-INDUCED PHARMACEUTICAL PHARMACODYNAMIC RESPONSE |
RS61377B1 (en) | 2012-07-26 | 2021-02-26 | Camurus Ab | Opioid formulations |
MX366159B (en) | 2012-11-30 | 2019-07-01 | Acura Pharmaceuticals Inc | Self-regulated release of active pharmaceutical ingredient. |
US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
CA2899455C (en) | 2013-01-30 | 2021-06-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
JP6539274B2 (en) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Extruded immediate release abuse deterrent pills |
US9763912B2 (en) | 2013-10-30 | 2017-09-19 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions, methods of use, and methods of treatment |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015145459A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
ES2809458T3 (en) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Liquid filled, abuse deterrent and immediate release dosage form |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
CA2977814A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
EP3318252A1 (en) * | 2016-11-08 | 2018-05-09 | Alpex Pharma SA | Extended release tablet comprising a weight-loss drug |
JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Device and method for transdermal drug delivery |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
WO2019232077A1 (en) | 2018-05-29 | 2019-12-05 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
EP3893877A4 (en) | 2018-12-11 | 2022-09-14 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
CA3150767A1 (en) * | 2019-08-12 | 2021-02-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions comprising a combination of opioid antagonists |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0759303A1 (en) * | 1994-04-22 | 1997-02-26 | Yamanouchi Pharmaceutical Co. Ltd. | Colon-specific drug release system |
WO2000044353A1 (en) * | 1999-01-29 | 2000-08-03 | Losan Pharma Gmbh | Pharmaceutical compositions |
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
Family Cites Families (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) | 1960-11-29 | |||
US3493657A (en) * | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (en) | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) * | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4175119A (en) * | 1978-01-11 | 1979-11-20 | Porter Garry L | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
NO154582C (en) | 1978-10-20 | 1986-11-05 | Ferrosan Ab | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DIPHENYL-DIBUTYLPIPERAZINE CARBOXAMIDS. |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4587118A (en) | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4424205A (en) | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
JPS5951223A (en) * | 1982-09-17 | 1984-03-24 | Sumitomo Chem Co Ltd | Pharmaceutical composition |
JPS5951223U (en) | 1982-09-28 | 1984-04-04 | 曙ブレーキ工業株式会社 | Floating caliper type disc brake |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4681897A (en) | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
DE3434946A1 (en) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (en) | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
EP0452765B1 (en) * | 1985-09-11 | 1999-10-20 | Btg International Limited | Pharmaceutical composition and medical uses of dioxopiperidine derivatives, especially as immune response potentiators, antiviral and antibacterial agents |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
US4939149A (en) | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5403868A (en) * | 1988-12-23 | 1995-04-04 | Sandoz Ltd. | Capsaicin derivatives |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
ES2081477T3 (en) | 1990-04-24 | 1996-03-16 | Teijin Ltd | PATCH. |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
KR100221695B1 (en) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
RU2121346C1 (en) | 1991-09-06 | 1998-11-10 | МакНейлэб, Инк. | Composition containing substance tramadol and acetaminophen and a method of treatment using thereof |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
EP0623155A4 (en) | 1991-09-18 | 1995-01-11 | Transcontinental Marketing Gro | One coat protective system for a surface. |
US5226331A (en) | 1991-10-03 | 1993-07-13 | General Electric Company | Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
GB9203689D0 (en) * | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
ATE404201T1 (en) * | 1992-06-22 | 2008-08-15 | Univ California | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5633259A (en) * | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
JPH0710745Y2 (en) | 1993-01-27 | 1995-03-15 | 吉範 安田 | Nursing sheets |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
JPH0710745A (en) * | 1993-06-22 | 1995-01-13 | Tanabe Seiyaku Co Ltd | Oral preparation for release-starting time control type intestinal delivery |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ES2377126T3 (en) * | 1994-12-12 | 2012-03-22 | Omeros Corporation | Irrigation solution and use thereof for perioperative inhibition of pain, inflammation and / or spasms in a vascular structure |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5762963A (en) * | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
HUP9700322A3 (en) | 1995-06-09 | 2001-03-28 | Euro Celtique Sa | Formulations and methods for providing prolonged local anesthesia |
SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
JP3185206B2 (en) * | 1995-07-20 | 2001-07-09 | 田辺製薬株式会社 | Lower digestive tract release coated capsule formulation |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
CA2239301A1 (en) | 1995-12-06 | 1997-06-12 | Charles Howard Mitch | Composition for treating pain |
DE69709646T2 (en) * | 1996-03-12 | 2002-08-14 | Alza Corp | COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
JPH10338634A (en) * | 1997-04-11 | 1998-12-22 | Grelan Pharmaceut Co Ltd | Medicinal composition |
WO1999001111A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
US5891919A (en) * | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
AU773642C (en) * | 1997-12-22 | 2006-04-06 | Mundipharma Pty Limited | Opioid agonist/antagonist combinations |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
EP2020229A1 (en) * | 1998-11-02 | 2009-02-04 | Elan Pharma International Limited | Multiparticulate modified release composition |
GB9905558D0 (en) | 1999-03-11 | 1999-05-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
PT2092936E (en) * | 2000-02-08 | 2013-06-20 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
CN1592609A (en) * | 2001-05-11 | 2005-03-09 | 恩德制药公司 | Abuse-resistant opioid dosage form |
US20030064122A1 (en) * | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
US7968119B2 (en) * | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
DE10250084A1 (en) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US7867511B2 (en) | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
-
2002
- 2002-08-01 US US10/208,817 patent/US20030044458A1/en not_active Abandoned
- 2002-08-05 BR BR0211781-9A patent/BR0211781A/en not_active Application Discontinuation
- 2002-08-05 KR KR1020087030854A patent/KR20090005247A/en not_active Application Discontinuation
- 2002-08-05 ES ES02761250T patent/ES2337664T3/en not_active Expired - Lifetime
- 2002-08-05 DE DE20220838U patent/DE20220838U1/en not_active Expired - Lifetime
- 2002-08-05 DK DK02761250.6T patent/DK1414459T3/en active
- 2002-08-05 EP EP02761250A patent/EP1414459B1/en not_active Expired - Lifetime
- 2002-08-05 KR KR1020047001854A patent/KR100893895B1/en active IP Right Grant
- 2002-08-05 MX MXPA04001098A patent/MXPA04001098A/en active IP Right Grant
- 2002-08-05 WO PCT/US2002/024889 patent/WO2003013538A1/en active Application Filing
- 2002-08-05 HU HU0401066A patent/HUP0401066A2/en unknown
- 2002-08-05 RU RU2004106620/15A patent/RU2004106620A/en not_active Application Discontinuation
- 2002-08-05 SI SI200230884T patent/SI1414459T1/en unknown
- 2002-08-05 CA CA2456601A patent/CA2456601C/en not_active Expired - Lifetime
- 2002-08-05 PT PT02761250T patent/PT1414459E/en unknown
- 2002-08-05 JP JP2003518547A patent/JP5143995B2/en not_active Expired - Lifetime
- 2002-08-05 AT AT02761250T patent/ATE450259T1/en active
-
2004
- 2004-09-23 US US10/948,575 patent/US7384653B2/en not_active Ceased
- 2004-11-03 HK HK04108654.6A patent/HK1067524A1/en not_active IP Right Cessation
-
2008
- 2008-06-06 AU AU2008202531A patent/AU2008202531A1/en not_active Abandoned
- 2008-11-19 JP JP2008295477A patent/JP5485538B2/en not_active Expired - Fee Related
-
2010
- 2010-02-12 CY CY20101100149T patent/CY1109816T1/en unknown
-
2013
- 2013-05-13 JP JP2013101285A patent/JP2013189447A/en active Pending
- 2013-10-28 US US13/923,362 patent/USRE45822E1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0759303A1 (en) * | 1994-04-22 | 1997-02-26 | Yamanouchi Pharmaceutical Co. Ltd. | Colon-specific drug release system |
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
WO2000044353A1 (en) * | 1999-01-29 | 2000-08-03 | Losan Pharma Gmbh | Pharmaceutical compositions |
Cited By (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9474750B2 (en) | 1997-12-22 | 2016-10-25 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
US8936808B1 (en) | 1997-12-22 | 2015-01-20 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US9168252B2 (en) | 2001-05-11 | 2015-10-27 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9283221B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9056051B2 (en) | 2001-05-11 | 2015-06-16 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9084729B2 (en) | 2001-05-11 | 2015-07-21 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9161937B2 (en) | 2001-05-11 | 2015-10-20 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9511066B2 (en) | 2001-05-11 | 2016-12-06 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9480685B2 (en) | 2001-05-11 | 2016-11-01 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9283216B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9358230B1 (en) | 2001-05-11 | 2016-06-07 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9345701B1 (en) | 2001-05-11 | 2016-05-24 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9820982B2 (en) | 2001-07-06 | 2017-11-21 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US9907793B2 (en) | 2002-04-05 | 2018-03-06 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US9655855B2 (en) | 2002-04-05 | 2017-05-23 | Purdue Pharma L.P. | Matrix for sustained, invariant and independent release of active compounds |
US10420762B2 (en) | 2002-04-05 | 2019-09-24 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US10004693B2 (en) | 2002-04-09 | 2018-06-26 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US9814684B2 (en) | 2002-04-09 | 2017-11-14 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
EP2422773A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
EP2422775A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
EP2422772A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
WO2004037230A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form that is safeguarded from abuse |
EP1581188A4 (en) * | 2003-01-10 | 2006-04-05 | Mutual Pharmaceutical Co | Pharmaceutical safety dosage forms |
EP1581188A1 (en) * | 2003-01-10 | 2005-10-05 | Mutual Pharmaceutical Company, Inc. | Pharmaceutical safety dosage forms |
JP2006524261A (en) * | 2003-04-21 | 2006-10-26 | ユーロ−セルティーク エス.エイ. | Anti-modified dosage form containing coextrusion adverse agent particles and process for producing the same |
JP2011157384A (en) * | 2003-04-21 | 2011-08-18 | Euro-Celtique Sa | Tamper resistant dosage form comprising co-extruded adverse agent particle and method for making the same |
US9750699B2 (en) | 2003-06-20 | 2017-09-05 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
US8877232B2 (en) | 2003-06-20 | 2014-11-04 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
US9943485B2 (en) | 2003-06-20 | 2018-04-17 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US7976847B2 (en) | 2004-01-13 | 2011-07-12 | Vasogenix Pharmaceuticals, Inc. | Controlled release CGRP delivery composition for cardiovascular and renal indications |
JP2007517913A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ, インコーポレイテッド | Method for treating acute myocardial infarction by administering calcitonin gene-related peptide and composition containing calcitonin gene-related peptide |
JP2007517912A (en) * | 2004-01-13 | 2007-07-05 | バソジェニックス ファーマシューティカルズ, インコーポレイテッド | Controlled release CGRP delivery composition for cardiovascular and renal indications |
US8298579B2 (en) | 2004-03-30 | 2012-10-30 | Euro-Celtique S.A. | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
US9795681B2 (en) | 2004-03-30 | 2017-10-24 | Purdue Pharma L.P. | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
CN1984658B (en) * | 2004-06-08 | 2012-04-18 | 欧洲凯尔特公司 | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
JP2008501750A (en) * | 2004-06-08 | 2008-01-24 | ユーロ−セルティーク エス.エイ. | Opioids for the treatment of chronic obstructive pulmonary disease (COPD) |
EP2283843A3 (en) * | 2004-06-08 | 2011-05-18 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
WO2005120506A1 (en) * | 2004-06-08 | 2005-12-22 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
JP4669878B2 (en) * | 2004-06-08 | 2011-04-13 | ユーロ−セルティーク エス.エイ. | Opioids for the treatment of chronic obstructive pulmonary disease (COPD) |
EP1961421A1 (en) * | 2004-06-08 | 2008-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
AU2005251445B2 (en) * | 2004-06-08 | 2008-09-04 | Mundipharma Pty Limited | Opioids for the treatment of the restless leg syndrome |
AU2005251445C1 (en) * | 2004-06-08 | 2009-04-09 | Mundipharma Pty Limited | Opioids for the treatment of the restless leg syndrome |
WO2005120507A1 (en) * | 2004-06-08 | 2005-12-22 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (copd) |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
AU2005251445B8 (en) * | 2004-06-08 | 2008-09-18 | Mundipharma Pty Limited | Opioids for the treatment of the restless leg syndrome |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
EP1809259A4 (en) * | 2004-10-15 | 2012-12-12 | Supernus Pharmaceuticals Inc | Less abusable pharmaceutical preparations |
EP1809259A2 (en) * | 2004-10-15 | 2007-07-25 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
US9744151B2 (en) | 2004-11-22 | 2017-08-29 | Svc Pharma Lp | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol |
US8383842B2 (en) | 2004-11-22 | 2013-02-26 | Purdue Pharma L.P. | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol |
US9278083B2 (en) | 2004-11-22 | 2016-03-08 | Svc Pharma Lp | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol |
US9675581B2 (en) | 2004-11-22 | 2017-06-13 | Svc Pharma Lp | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans- (+)-Δ9-tetrahydrocannabinol |
US8937097B2 (en) | 2004-11-22 | 2015-01-20 | Purdue Pharma L.P. | Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
WO2006133733A1 (en) * | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
EP1893183A1 (en) * | 2005-06-13 | 2008-03-05 | Paul Rosenberg | Emetic embedded capsule |
WO2006134018A3 (en) * | 2005-06-13 | 2007-03-08 | Flamel Tech Sa | Oral dosage form comprising an antimisuse system |
EP1893183A4 (en) * | 2005-06-13 | 2010-08-18 | Paul Rosenberg | Emetic embedded capsule |
US9060950B2 (en) | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
JP2008543746A (en) * | 2005-06-13 | 2008-12-04 | フラメル・テクノロジーズ | Oral dosage form including abuse prevention system |
AU2006259199B2 (en) * | 2005-06-13 | 2011-11-24 | Flamel Ireland Limited | Oral dosage form comprising an antimisuse system |
WO2007013975A2 (en) * | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
WO2007013975A3 (en) * | 2005-07-20 | 2007-04-05 | Pharmorx Inc | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
US8445023B2 (en) | 2005-11-10 | 2013-05-21 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
WO2007070632A2 (en) * | 2005-12-13 | 2007-06-21 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
AU2006326377B2 (en) * | 2005-12-13 | 2010-10-07 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
WO2007070632A3 (en) * | 2005-12-13 | 2007-10-11 | Biodelivery Sciences Internati | Abuse resistant transmucosal drug delivery device |
US9522188B2 (en) | 2005-12-13 | 2016-12-20 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
US10632205B2 (en) | 2006-05-12 | 2020-04-28 | Intellipharmaceutics Corp | Pharmaceutical composition having reduced abuse potential |
US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US9655843B2 (en) | 2006-07-21 | 2017-05-23 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US9597288B2 (en) | 2006-07-21 | 2017-03-21 | Biodelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
US8920834B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US8920833B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US8691270B2 (en) | 2007-12-17 | 2014-04-08 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US8927013B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US8927014B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
US9820983B2 (en) | 2009-03-10 | 2017-11-21 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
CN102858324A (en) * | 2010-03-24 | 2013-01-02 | L.莫尔特尼及阿利蒂兄弟联合股份公司 | Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
WO2011117306A1 (en) * | 2010-03-24 | 2011-09-29 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
ITFI20100047A1 (en) * | 2010-03-24 | 2011-09-25 | Molteni & C | PHARMACEUTICAL FORMULATIONS BISTRATO CONTAINING OPPOSING AGONISTS AND ANTAGONISTS. |
US10786457B2 (en) | 2010-04-01 | 2020-09-29 | Theravida, Inc. | Pharmaceutical formulations |
US9968556B2 (en) | 2010-04-01 | 2018-05-15 | Theravida, Inc. | Pharmaceutical formulations |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9585893B2 (en) | 2011-02-23 | 2017-03-07 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
US9744157B2 (en) | 2011-05-10 | 2017-08-29 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2014059512A1 (en) * | 2012-10-15 | 2014-04-24 | Isa Odidi | Oral drug delivery formulations |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11779569B2 (en) | 2016-01-20 | 2023-10-10 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US10610519B2 (en) | 2016-01-20 | 2020-04-07 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US10328057B2 (en) | 2016-01-20 | 2019-06-25 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US11185533B2 (en) | 2016-01-20 | 2021-11-30 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US10046032B2 (en) | 2016-03-24 | 2018-08-14 | Nutrinia, Ltd. | Use of insulin for promoting gastric emptying |
WO2019173062A1 (en) * | 2018-03-07 | 2019-09-12 | Trucapsol, Llc | Reduced permeability microcapsules |
US11007501B2 (en) | 2018-03-07 | 2021-05-18 | Trucapsol Llc | Reduced permeability microcapsules |
US11344502B1 (en) | 2018-03-29 | 2022-05-31 | Trucapsol Llc | Vitamin delivery particle |
US11794161B1 (en) | 2018-11-21 | 2023-10-24 | Trucapsol, Llc | Reduced permeability microcapsules |
US11571674B1 (en) | 2019-03-28 | 2023-02-07 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11542392B1 (en) | 2019-04-18 | 2023-01-03 | Trucapsol Llc | Multifunctional particle additive for enhancement of toughness and degradation in biodegradable polymers |
US11547978B2 (en) | 2020-01-30 | 2023-01-10 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11484857B2 (en) | 2020-01-30 | 2022-11-01 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11465117B2 (en) | 2020-01-30 | 2022-10-11 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11878280B2 (en) | 2022-04-19 | 2024-01-23 | Trucapsol Llc | Microcapsules comprising natural materials |
US11904288B1 (en) | 2023-02-13 | 2024-02-20 | Trucapsol Llc | Environmentally biodegradable microcapsules |
Also Published As
Publication number | Publication date |
---|---|
RU2004106620A (en) | 2005-04-10 |
JP5143995B2 (en) | 2013-02-13 |
KR100893895B1 (en) | 2009-04-20 |
BR0211781A (en) | 2004-07-27 |
HK1067524A1 (en) | 2005-04-15 |
JP2013189447A (en) | 2013-09-26 |
JP5485538B2 (en) | 2014-05-07 |
JP2009132711A (en) | 2009-06-18 |
ATE450259T1 (en) | 2009-12-15 |
USRE45822E1 (en) | 2015-12-22 |
EP1414459B1 (en) | 2009-12-02 |
US7384653B2 (en) | 2008-06-10 |
HUP0401066A2 (en) | 2004-08-30 |
CY1109816T1 (en) | 2014-09-10 |
DE20220838U1 (en) | 2004-05-19 |
SI1414459T1 (en) | 2010-04-30 |
KR20090005247A (en) | 2009-01-12 |
JP2005520783A (en) | 2005-07-14 |
US20030044458A1 (en) | 2003-03-06 |
PT1414459E (en) | 2010-03-03 |
AU2008202531A1 (en) | 2008-07-03 |
CA2456601C (en) | 2012-04-24 |
MXPA04001098A (en) | 2004-05-20 |
EP1414459A1 (en) | 2004-05-06 |
KR20040043181A (en) | 2004-05-22 |
US20050063909A1 (en) | 2005-03-24 |
CA2456601A1 (en) | 2003-02-20 |
DK1414459T3 (en) | 2010-04-12 |
ES2337664T3 (en) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE45822E1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
EP2283842B1 (en) | Tamper-resistant oral opioid agonist formulations | |
EP2034975B1 (en) | Pharmaceutical compositions | |
US20090041838A1 (en) | Anti-Misuse Microparticulate Oral Drug Form | |
AU2017204639A1 (en) | Pharmaceutical composition comprising opioid agonist and sequestered antagonist | |
MXPA05011071A (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same. | |
EP2073797A2 (en) | Pharmaceutical compositions | |
AU2011205217B2 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
AU2002326529A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160195 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001098 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2456601 Country of ref document: CA Ref document number: 2003518547 Country of ref document: JP Ref document number: 2002761250 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047001854 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002326529 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 466/CHENP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002761250 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |